Myeloma is a plasma cell dyscrasia, which is categorized as a B-cell neoplasia. It is usually incurable with a median survival period of 3-4 years. There are serious problems in treating patients with myeloma. Myeloma cells themselves are not merely less sensitive to chemotherapy due to their dormancy but prone to becoming drug resistant. The incidence of myeloma increases with age and the median age at diagnosis is B70 years. Currently, several new agents, such as bortezomib, lenalidomide and thalidomide, are clinically available for single or combined use for induction and maintenance. However, results have not been satisfactory with regard to overall survival and event-free survival. Thus, new therapeutic options are needed for patients with myeloma. Myeloma cells show the strong expression of CD38, but no expression of CD19 on their surface, differing from other hematologic malignancies containing B-cell neoplasms. Generally, in normal hematopoiesis, CD38 expression on the cell surface is restricted to lineage-committed precursors. 1 According to gene chip profiling, the expression of mRNA for CD38 is restricted to the thymus, bone marrow and prostate, suggesting that CD38 is a feasible target for immunotherapy. Immunotherapy including antibody treatment acts on cells, which have not entered the cell cycle and is desirable for aged patients because of fewer adverse effects. Thus, we investigated whether the retroviral vector-mediated transduction of an anti-CD38-chimeric antigen receptor (CAR) gene, which we developed previously, 2 contributed to the abrogation of myeloma cells. Here we report that T-cell immunotherapy with the anti-CD38-CAR is quite effective in eliminating myeloma cells highly expressing the CD38 molecule.
Two myeloma cell lines (RPMI8226 and KMM1) were cultured in RPMI-1640 medium supplemented with 10% fetal calf serum at 37 1C. Primary myeloma cells obtained from bone marrow aspirate of patients, peripheral blood cells from healthy donors and those from a patient (Patient 5) in autologous settings were subjected to Ficoll-density centrifugation. Informed consent was obtained from all of these patients and donors. Patients with myeloma and donors were examined as approved by the institutional review board at Hiroshima University and Fukuyama Central Hospital. The retroviral vector construct consisting of green fluorescein protein, the transmembrane domain of CD8a, the intracellular domains of 4-1BB, CD3z and anti-CD38 single-chain variable domain (scFv) was reported previously. 2 Peripheral blood mononuclear cells stimulated with PHA-M and IL-2 were transduced in virus-conditioned medium with polybrene in a polypropylene tube coated with fibronectin by spinoculation. The addition of anti-CD38 antibody (CPK-H; MBL, Nagoya, Japan) was used to protect transduced T cells from auto-lysis through cross-linking of anti-CD38-CAR with intrinsic CD38, because activated T cells express CD38 on their cell surface. 2 Briefly, to increase the number of T cells with anti-CD38-CAR and maintain the viability of the cells, we replaced the medium containing the antibody (0.15 mg/ml) and IL-2 (200 IU/ml) every 4-5 days until 14 days post-transduction. For the co-culture experiment, T cells were washed with phosphate-buffered saline and complete medium several times to eliminate the effect of residual antibodies in the medium. To detect surface expression of the anti-CD38-CAR, cells were stained with a goat anti-mouse (Fab') 2 polyclonal antibody conjugated to biotin followed by streptavidin-PerCP. Cytotoxicity of the transduced cells was assessed by flow cytometric analysis as described. 2 We had previously designed the retroviral vector carrying anti-CD38-CAR and green fluorescein protein genes. 2 T cells obtained from healthy donors were transduced with retroviral supernatant containing the anti-CD38-CAR vector. The anti-CD38-CAR was expressed with high efficiency. The median percentage of transduced cells was 65.89% (range, 48.98-89.98%; n ¼ 8). We confirmed the expression of the anti-CD38-CAR by flow cytometry using a goat-anti-mouse polyclonal antibody conjugated to biotin followed by streptavidin-PerCP, which reacts with the extracellular antibody-derived scFv of the anti-CD38-CAR ( Figure 1a ). To assess their cytotoxicity, the T cells transduced with the anti-CD38-CAR were incubated with the KMM1 and RPMI8226 myeloma cell lines for 3 days at a variety of effector (E):target (T) ratios. The transduced cells exerted a highly cytotoxic effect on RPMI8226 cells in a timedependent manner ( Figure 1b) . As shown in Figure 1c , the chimeric receptor-mediated cytotoxicity was dose dependent. Table 1 shows the specific cytotoxicity of T cells with the anti-CD38-CAR to myeloma cell lines at an E:T ratio of 0.5:1.
Representative data are shown in Figure 1d . By contrast, there was no detectable cytotoxicity in experiments with the U266-A4 cells, lacking CD38 expression (0.05%) ( Table 1 ). These results demonstrated that CD38-specific T cells from donors effectively exerted a cytotoxic effect on myeloma cell lines in a dose-and time-dependent fashion.
We next evaluated the effect of the anti-CD38-specific T cells on myeloma cells from the patients (Table 1) . Myeloma cells freshly isolated from the five patients accounted for over 80% of the cells in bone marrow. After myeloma cells were co-cultured with T cells bearing the anti-CD38-CAR for 3 days, cytotoxic activity was assessed as described above. Intriguingly, mean ( ± s.d.) specific cytotoxicity observed at an E:T ratio of 0.5: 1 for 3 days was 490% in individual patients (Table 1) . Bone marrow and peripheral blood from Patient 5 were used in autologous settings. Representative flow cytometric data on Patient 5 are shown in Figure 1d . These results showed that T cells harboring the anti-CD38-CAR definitively eliminated myeloma cells from the patients as well as myeloma cell lines. 
Letters to the Editor
Anti-CD38 antibodies or antibody variants have been shown to provide therapeutics for the treatment of CD38-positive hematological malignancies. [3] [4] [5] [6] [7] Introduction of the antibody against CD38 may, however, raise concerns of side effects such as an infusion reaction and pharmacological phenomena associated with the long half-life of the antibody. Although antibodies against CD38 have been administered to patients with myeloma or B-cell lymphoma, there has been no report of adverse effects. 7, 8 Indeed, daratumumab, a novel therapeutic human CD38 antibody and humanized monoclonal CD38 antibody (SAR650984) (http://clinicaltrialsfeeds.org/clinical-trials/ show/NCT01084252), is currently in clinical trials. This therapeutic option could be ready for use anytime without manipulation of cells and may be useful for most myeloma patients. Instead, to exert an effect of the antibody, effector cells are required through ADCC. Autologous T-cell immunotherapy with anti-CD38-CAR has a powerful tool for myeloma treatment. However, this method has some restrictions. First of all, cytotoxicity is dependent on the proliferation of T cells and transduction efficiency of anti-CD38-CAR into the effector T cells. Second, highly profound manipulation and culture duration of effector T cells are required. Third, abundant T cells might induce cytokine storm, which may affect patients' conditions. Therefore, this immunotherapy may favorably be performed in the patients with lower load of refractory myeloma cells. Moreover, it can be applicable for the patients with myeloma cell infiltration in their brain and with masses, because T cells can penetrate through the blood-brain barrier and infiltrate into the masses through the vessels.
In this study, we demonstrated that human T cells with the anti-CD38-CAR were highly cytotoxic against myeloma cells strongly expressing CD38. Improvements to immunotherapy using autologous T cells transduced with the anti-CD38-CAR might shed further light on the treatment of myeloma patients with a poor prognosis.
DNA methylation pattern is altered in childhood T-cell acute lymphoblastic leukemia patients as compared with normal thymic subsets: insights into CpG island methylator phenotype in T-ALL The therapy success rate for T-cell acute lymphoblastic leukemia (T-ALL) is significantly lower than that for precursor B-cell acute lymphoblastic leukemia. Relapse of the disease and therapy-related toxicity are the most common causes of unfavorable outcome. Therefore, accurate stratification is essential to avoid both undertreatment and overtreatment of patients. T-cell receptor gene-based minimal residual disease (MRD) quantification is so far the only most clinically relevant prognostic factor in T-ALL.
1,2 However, as it is laborious and time consuming, there is an urgent need for identification of novel prognostic factors in T-ALL.
Hypermethylation of CpG islands is a recognized mechanism of inactivation of tumor suppressor genes, associated with neoplastic transformation. Different cancer types are characterized by unique methylation patterns, which could be useful for diagnostic and prognostic purposes. 3 However,
